ld乐动强生公司创新LLC和詹森朝鲜Ltd. Announce Launch of Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
- QuickFire Challenge calls on innovators to submit potentially groundbreaking ideas or technologies that aim to enhance scientific progress across a range of focus areas.
- Awardee(s) will receive grant funding up to KRW150,000,000,1two years of residency at the Seoul Bio Hub, access to the Johnson & Johnson Innovation’s Asia Pacific ecosystem, including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts across the Johnson & Johnson Family of Companies.
SEOUL, KOREA, 8 JUNE 2022– Johnson & Johnson Innovation LLC and Janssen Korea Ltd. today announced the launch of theSeoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrowin collaboration with the Seoul Metropolitan Government (SMG) and the Korea Health Industry Development Institute (KHIDI). The challenge, which is the sixth in the Seoul Innovation series, invites innovators from around the world – including individuals, entrepreneurs, academics, biotech researchers, and early-stage companies – to submit potentially groundbreaking ideas or technologies that aim to enhance scientific progress across a range of focus areas, including oncology, immunology, infectious disease, neuroscience, cardiovascular and metabolic diseases, retinal diseases, pulmonary hypertension, and vision.
Awardee(s) can receive grant funding up to KRW150,000,000,1,2two years of residency at the Seoul Bio Hub, access to the Johnson & Johnson Innovation’s Asia Pacific ecosystem, including a dedicated workstation for one year at JLABS @ Shanghai, and mentorship from experts across the Johnson & Johnson Family of Companies.
“Johnson & Johnson Innovation is excited to continue collaborating with SMG and KHIDI on the Seoul Innovation QuickFire Challenge series with the aim to help address great unmet medical needs as part of Seoul’s growing biomedical ecosystem,” saidMelinda Richter, Global Head, Johnson & Johnson Innovation – JLABS.3“今年,我们呼吁创新者工作交流ross a number of critical focus areas - from cell therapy to next generation biosensors - to apply for the chance to tap into resources within the Korean and broader Asia Pacific ecosystem."
The QuickFire Challenge aims to advance breakthrough ideas for potential healthcare solutions by combining Johnson & Johnson Innovation’s unique vision for collaboration with the Seoul Metropolitan Government’s efforts to drive innovation and commercialize its research outcomes; Korea Health Industry Development Institute’s professional and systems-building support; and the Seoul Bio Hub’s ability to help accelerate the development and commercialization of potential early-stage, life-science solutions.
“We’ve seen exciting potential scientific advancements from awardees of the Seoul Innovation QuickFire Challenge series as a dedicated partner of Korean innovators over the past six years,” saidCherry Huang, Area Managing Director, Janssen North Asia.4“We’re excited to continue to cultivate paradigm-shifting scientific innovations such as cell therapy, precision medicine, or AI diagnostics in various therapeutic areas here in Seoul that have the potential to impact patients across the world.”
In addition to residency at Seoul Bio Hub, awardees can access a dedicated workstation at JLABS @ Shanghai, a state-of-the art 4,400 square-meter healthcare incubator, which is the first Johnson & Johnson Innovation - JLABS location established in Asia Pacific to serve the greater region.
Johnson & Johnson Innovation has developed the QuickFire Challenge platform with the aim to help enable potential groundbreaking science and health solutions by encouraging students, entrepreneurs, researchers, and start-up companies to tackle some of the world’s most challenging problems in healthcare.
This announcement marks the sixth QuickFire Challenge in Korea, following the launch of the previous Seoul Innovation QuickFire Challenges in August 2017, August 2018, July 2019, June 2020, and May 2021.
The deadline to apply is July 15, 2022. For more information about theSeoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow(including the terms and conditions of entry), please visit: http://jji.jnj/seoul-innovation.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us atwww.jnjinnovation.com.
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism, & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Learn more at www.janssen.com. Follow us at www.twitter.com/JanssenGlobal. Janssen Korea Ltd. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Cautions Concerning Forward-Looking Statements
本新闻稿中包含“前瞻性的状态ments" as defined in the Private Securities Litigation Reform Act of 1995 related to the launch of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation LLC and Janssen Korea Ltd. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The Johnson & Johnson Innovation LLC and Janssen Korea Ltd. and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
Media Contacts:
Johnson & Johnson Innovation LLC:
Jieying Wu
+86 139 1171 2835
[email protected]
